Johnson & Johnson (NYSE:JNJ) Stock Position Lifted by Toth Financial Advisory Corp

Toth Financial Advisory Corp increased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 62,847 shares of the company’s stock after buying an additional 1,091 shares during the period. Johnson & Johnson comprises approximately 1.2% of Toth Financial Advisory Corp’s holdings, making the stock its 23rd biggest position. Toth Financial Advisory Corp’s holdings in Johnson & Johnson were worth $9,942,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Keener Financial Planning LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $40,000. WFA Asset Management Corp increased its holdings in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at about $44,000. Disciplined Equity Management Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $45,000. Finally, Grayhawk Investment Strategies Inc. increased its position in Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price for the company. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Morgan Stanley decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 20th. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $146.16 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The company has a market cap of $351.76 billion, a P/E ratio of 9.11, a price-to-earnings-growth ratio of 2.43 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The firm’s 50 day simple moving average is $148.14 and its 200-day simple moving average is $154.06.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the previous year, the company posted $2.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.